As of 2026-03-06, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (0.81) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -109.5%.
The range of the Relative Valuation is (0.73) - (0.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.6x - 26.5x | 23.4x |
| Forward P/E multiples | 20.5x - 24.2x | 22.4x |
| Fair Price | (0.73) - (0.86) | (0.81) |
| Upside | -108.6% - -110.1% | -109.5% |
| Date | P/E |
| 2026-03-02 | -243.83 |
| 2026-02-27 | -247.22 |
| 2026-02-26 | -223.20 |
| 2026-02-25 | -213.32 |
| 2026-02-24 | -215.01 |
| 2026-02-23 | -214.16 |
| 2026-02-20 | -210.49 |
| 2026-02-19 | -211.34 |
| 2026-02-18 | -205.12 |
| 2026-02-17 | -196.36 |
| 2026-02-13 | -191.00 |
| 2026-02-12 | -192.13 |
| 2026-02-11 | -193.26 |
| 2026-02-10 | -185.06 |
| 2026-02-09 | -178.00 |
| 2026-02-06 | -180.26 |
| 2026-02-05 | -176.30 |
| 2026-02-04 | -181.39 |
| 2026-02-03 | -189.30 |
| 2026-02-02 | -187.32 |
| 2026-01-30 | -185.91 |
| 2026-01-29 | -188.45 |
| 2026-01-28 | -188.17 |
| 2026-01-27 | -191.00 |
| 2026-01-26 | -193.82 |
| 2026-01-23 | -191.84 |
| 2026-01-22 | -190.71 |
| 2026-01-21 | -189.87 |
| 2026-01-20 | -188.45 |
| 2026-01-16 | -188.17 |
| 2026-01-15 | -202.58 |
| 2026-01-14 | -191.56 |
| 2026-01-13 | -190.71 |
| 2026-01-12 | -200.32 |
| 2026-01-09 | -209.08 |
| 2026-01-08 | -215.29 |
| 2026-01-07 | -223.77 |
| 2026-01-06 | -214.16 |
| 2026-01-05 | -209.36 |
| 2026-01-02 | -211.90 |
| 2025-12-31 | -220.38 |
| 2025-12-30 | -216.42 |
| 2025-12-29 | -217.84 |
| 2025-12-26 | -215.58 |
| 2025-12-24 | -217.55 |
| 2025-12-23 | -212.75 |
| 2025-12-22 | -215.01 |
| 2025-12-19 | -209.36 |
| 2025-12-18 | -205.97 |
| 2025-12-17 | -201.45 |